SEC Form 4 · accession 0001209191-15-040221

VERTEX PHARMACEUTICALS INC / MA · VRTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

May 6, 2015

Accepted (ET)

May 7, 2015 · 7:37 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000875320

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	May 6, 2015	M	1,300	$17.16	A	387,584	D
Common Stock	May 6, 2015	M	10,400	$35.64	A	397,984	D
Common Stock^F2,F3	May 6, 2015	S	3,600	$121.92	D	394,384	D
Common Stock^F3,F4	May 6, 2015	S	4,500	$122.84	D	389,884	D
Common Stock^F3,F5	May 6, 2015	S	3,600	$123.61	D	386,284	D
Common Stock	holding	—	—		—	13,286	I	401(k)
Common Stock^F6	holding	—	—		—	122,700	I	Common Stock held in trust

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F7	$17.16	May 6, 2015	M	1,300	D	—	Jul 19, 2015	Common Stock	1,300	13,500	D
Stock Option (right to buy)^F7	$35.64	May 6, 2015	M	10,400	D	—	Feb 1, 2016	Common Stock	10,400	396,000	D

F1Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
F2Open market sales reported on this line occurred at a weighted average price of $121.92 (range $121.38 to $122.34).
F3Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4Open market sales reported on this line occurred at a weighted average price of $122.84 (range $122.39 to $123.34).
F5Open market sales reported on this line occurred at a weighted average price of $123.61 (range $123.40 to $123.93).
F6Common stock held in grantor retained annuity trusts.
F7Fully vested.